Sharper scans may spare prostate patients from radiation side effects
NCT ID NCT00890006
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether using advanced MRI and daily CT scans during radiation therapy for low- to intermediate-risk prostate cancer can reduce side effects like bowel, bladder, and erectile problems. About 99 men will receive standard radiation but with more precise imaging to guide treatment. The goal is to see if this approach lowers the chance of moderate to severe side effects and improves quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Advanced imaging (MRI and daily cone-beam CT) for radiotherapy planning and guidance
- What this could lead to
- If successful, this approach could reduce common side effects like bowel, bladder, and erectile problems from prostate cancer radiation.
- What could go wrong
- This is a small, early-stage study (99 participants) focused on reducing side effects, not on curing cancer. The benefits may not be large or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
99 people
The number who actually took part.
- Start date
-
Sep 2006
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Low or intermediate risk localized prostate cancer: * Gleason score ≤ 7 * PSA \<20 * Stage T2a or less (Stage 2 only) * \<50% of biopsy cores involved with tumor (Stage 2 only) Exclusion Criteria: * History of hip replacement * Inflammatory bowel disease or collagen vascular disease * Contraindication to fiducial marker placement * Bleeding diathesis or anticoagulant therapy that cannot safely be ceased temporarily * Severe adverse event with prior TRUS-guided prostate biopsy * Patient refuses fiducial marker placement * Contraindication to MRI * Patient randomization in PROFIT Trial (Stage 2 only) * Patients not prescribed 78Gy in 39 fractions to the prostate gland.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Low or intermediate risk prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada